Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05712200 | Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76) | PHASE3 | RECRUITING | 1,900 | — | — | Dec 27, 2022 | Oct 31, 2026 | Mar 31, 2026 | 734 | United States, Argentina +32 |
| Arm | Type | Description |
|---|---|---|
| Abelacimab (MAA868) | EXPERIMENTAL | Patients will be randomized in a 1:1 ratio to receive abelacimab 150 mg subcutaneous (SC) or matching placebo once monthly. |
| Placebo | PLACEBO_COMPARATOR | Patients will be randomized in a 1:1 ratio to receive abelacimab 150 mg subcutaneous (SC) or matching placebo once monthly. |
| Name | Type | Description |
|---|---|---|
| Abelacimab | BIOLOGICAL | Abelacimab provided as liquid in vial (150 mg/mL) |
| Placebo | DRUG | Dosage Formulation: Liquid (in vial) Dose Strength: Placebo to Abelacimab |
Inclusion Criteria: * Patient is able to understand and has provided written informed consent to participate in the trial * Diagnosed Atrial Fibrillation (AF) or atrial flutter (documented on an electrocardiogram (ECG) or monitor recording) * Age 65-74 and a CHA2DS2VASc ≥4 OR age ≥75 and a CHA2DS2V...